Ovarian cancer combo trial halted: what we learned
Disease control
Terminated
This study tested a combination of two drugs, SON-1010 and atezolizumab, in people with advanced solid tumors and platinum-resistant ovarian cancer. The goal was to see if the combination was safe and could slow cancer growth. The study was terminated early, so results are limite…
Phase: PHASE1, PHASE2 • Sponsor: Sonnet BioTherapeutics • Aim: Disease control
Last updated May 01, 2026 15:56 UTC